Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NW300EMCBD cannabidiol formulation in healthy volunteers
NCT07186283Phase 1Completed
- Sponsor
- NW PharmaTech
- Start
- Sep 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NWPT-SM32300 (3 arms), sponsored by NW PharmaTech. Primary endpoint: Cannabidiol plasma concentration at 192 hours. Started Sep 2025; status: completed.
02
Drugs
NWPT-SM32300
Beyond the preview
Go deeper on NCT07186283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07186283.